Deferiprone, an iron chelator (binder) therapy, does not slow the progression of Parkinson’s disease in newly diagnosed patients who have never received treatment, according to data from a Phase 2 clinical trial. Instead, after about nine months of treatment in these patients, deferiprone was associated with a worsening of…
Levels of alpha-synuclein, beta-amyloid, and neurofilament light chain (NfL) in the cerebrospinal fluid (CSF) that surrounds the brain and the spinal cord can help identify Parkinson’s disease and distinguish it from atypical parkinsonism, according to a review study. The study, “A meta-analysis of the diagnostic…
The U.S. Food and Drug Administration (FDA) has put a hold on clinical trials of IkT-148009, an experimental oral therapy that Inhibikase Therapeutics is developing for Parkinson’s disease and other related and non-related conditions. The hold comes just a few months after Inhibikase started dosing Parkinson’s patients…
Vibra Healthcare is partnering with the neurotechnology company MindMaze to provide digital neurotherapeutic tools for people with neurological disorders both in the clinic and at home. The initiative will start with patients at select Vibra hospitals in Kentucky and California. MindMaze’s digital health solutions aim to help people with…
NeuroOne Medical Technologies announced it has successfully completed a feasibility study of its OneRF ablation system, which uses implanted electrodes to destroy targeted regions of the brain — and may help to control tremor in people with Parkinson’s disease — in animal models. The company is planning…
Largely for its complex and successful efforts to personalize treatment timing for Parkinson’s patients, the Vanderbilt University Medical Center (VUMC) has received The Joint Commission’s (TJC) Gold Seal of Approval for Parkinson’s Disease Certification. The Nashville, Tennessee-based VUMC is the nation’s second healthcare organization to receive the…
BioVie’s investigational oral therapy NE3107, taken in combination with standard levodopa, eases motor symptoms more substantially than levodopa alone in people with Parkinson’s disease, according to top-line results of a Phase 2 clinical trial. “NE3107 shows promise, and if the current findings are confirmed, it may represent one…
Combining Myrbetriq (mirabegron) with modifications like pelvic floor exercises failed to ease overactive bladder symptoms in people with Parkinson’s disease in a pilot clinical trial, the study’s main goal. But the treatment, approved for overactive bladder, when used with such behavioral modifications did increase the amount of urine patients were…
Blood levels of small vesicles originating in neurons and containing proteins related to Parkinson’s disease or Alzheimer’s disease — alpha-synuclein, phosphorylated tau, or insulin receptor substrate 1 (IRS-1) — can be biomarkers of cognitive impairment in Parkinson’s patients, a study reported. Changes in the levels of vesicles carrying these…
People with early-stage Parkinson’s disease may be about 70% less likely to catch the common cold than those with other common brain diseases, a Japanese study suggests. The study, “Are patients with Parkinson’s disease at a lower risk of catching the common cold? Propensity score matching,” was published…
Get regular updates to your inbox.
